Eosinophilic Esophagitis– Pipeline Review, 2019

Eosinophilic esophagitis is a chronic allergic or immune condition. Eosinophilic esophagitis results in inflammation of the esophagus. In eosinophilic esophagitis, a large number of white blood cells are found in the tissue of the esophagus. The symptoms of eosinophilic esophagitis include dysphagia, centrally located chest pain, upper abdominal pain, persistent heartburn, impaction, regurgitation, etc.

The causes of eosinophilic esophagitis include multiplication of eosinophils, damage to the esophagus, dysphagia and impaction, etc. Eosinophilic esophagitis is more common in males than female, and people who live in a cold or dry climate are affected more by the disease. The treatment of eosinophilic esophagitis includes dietary therapy and medications. Topical steroids such as fluticasone or budesonide and proton pump inhibitors are among the most common medications used for eosinophilic esophagitis.

Pharmaceutical companies and various research institutes are currently focusing on the development of new treatment options for eosinophilic esophagitis. For instance; APT-1011, which is being studied by Adare Pharmaceuticals, Inc., is currently in phase-2 clinical trials for the study of efficacy, safety, and pharmacokinetics of APT-1011 in subjects with eosinophilic esophagitis.

To know how our report can help streamline your business, Speak to Analyst

At present, over 50% of the pipeline candidates for eosinophilic esophagitis are in phase-2. More than half of the studies are sponsored by academic research institutes.

Report Description

The report on ‘Eosinophilic Esophagitis– Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Eosinophilic Esophagitis. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, and description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Eosinophilic Esophagitis.

The report on ‘Eosinophilic Esophagitis - Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players. 

Report Scope 

• Thorough assessment of the pipeline products by areas such as development stage; route of administration; drug class; indication; sponsor; molecule type and drug target
• Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration
• Overview of dormant and discontinued pipeline products
• Key insights in relation to the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products
• Overview of the latest developments; news articles, press releases and relevant conferences 

Report Methodology 

• All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.
• Desk research sources includes global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases 

Reasons to Buy this Report 

• Develop effective growth strategies based on comprehensive overview of the R&D activity and pipeline products for Eosinophilic Esophagitis
• Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players
• Identify the focus of leading players in relation to R&D for Eosinophilic Esophagitis
• Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business
• Analyse the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary